Skip to content

Clinical Efficacy and Intervention Mechanism of Cangyi Xiaoluo Formula in Children with Adenoid Hypertrophy

Clinical Efficacy and Intervention Mechanism of Cangyi Xiaoluo Formula in Children with Adenoid Hypertrophy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001294
Enrollment
Unknown
Registered
2026-05-26
Start date
2023-01-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoid hypertrophy in children

Interventions

Western Medicine Control Group:Mometasone furoate nasal spray / Nasonex (Dosage: Once daily, 5-11 years: 1 spray per nostril
12-18 years: 2 sprays per nostril). Leukotriene receptor antagonist (Singulair, 1 tablet nightly, chewable). One month constitutes one course of treatment, with a total of three courses.
TCM Treatment Group:Traditional Chinese Medicine (TCM) Group: Based on syndrome differentiation, the Cangyi Xiaoluo Formula granules are prescribed. The formula consists of: Xanthii Fructus, *Magn

Sponsors

Guangzhou Medical University Affiliated Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1) Children aged 2 to 12 years, regardless of sex; 2) Meet the Western diagnostic criteria for adenoid hypertrophy in children; 3) All enrolled children must have a signed informed consent form provided by their parents.

Exclusion criteria

Exclusion criteria: 1) Patients with primary cardiovascular, hepatic, renal, hematopoietic, or neurological diseases; 2) Individuals with OSA-18 scale scores indicating severe sleep impairment; 3) Patients with severe nasal deformities; 4) Individuals experiencing respiratory difficulties due to causes such as obesity, nasal polyps, neuromuscular tension in the upper airway, or laryngeal and tracheal disorders; 5) Patients who have received oral or intravenous antibiotics within the past 8 weeks; 6) Individuals allergic to the treatment medications; 7) Patients unable to cooperate with blood draw procedures; 8) Individuals who have participated in other clinical trials within the past 3 months.

Design outcomes

Primary

MeasureTime frame
Quantitative Score Comparison of Nasal Congestion, Snoring, and Mouth Breathing;Size of Adenoids;

Secondary

MeasureTime frame
Quantitative scoring of secondary symptoms and their changes;Quality of Life Assessment: OSA-18 Score;

Countries

CHINA

Contacts

Public ContactXU Fangwei

Guangzhou Medical University Affiliated Women and Children's Medical Center

13071182105@163.com13071182105

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026